Featured Content

Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center

Irradiation of Regional Nodes In Stage I - III Breast Cancer Patients Affects Overall Survival

(EORTC) Aug 3, 2015 - At a median follow-up of 10.9 years, an EORTC study has shown that irradiation of regional nodes in patients with stage I, II, or III breast cancer has a marginal effect on overall survival, the primary endpoint (at 10 years, overall survival was 82.3 % for regional irradiation versus 80.7% for no regional irradiation, (HR=0.87 (95%CI: 0.76, 1.00), p=0.06).

Commentary: The risk of local/regional recurrence varies widely in trials done in the United States compared to those in Europe...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Effective Ovarian Cancer Treatment Is Underused, Study Finds

(New York Times) Aug 3, 2015 - The treatment, known as IP, in which chemotherapy is pumped directly into the abdomen, could add 16 months or more to women’s lives, researchers say.
read article »

In Tough Diagnostics World, Will Ruling Out Cancer Be Good Business?

(Xconomy) Aug 4, 2015 - The high cost of cancer treatments is a huge topic of conversation these days. One way to trim those costs is to not give treatments to people who don’t need them.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Irradiation of Regional Nodes In Stage I - III Breast Cancer Patients Affects Overall Survival (EORTC)

The risk of local/regional recurrence varies widely in trials done in the United States compared to those in Europe...posted by: Debu Tripathy, MD

Op-Ed: Should We Charge Patients for Medical Research? (New York Times)

A very slippery ethical slope if "pay to play" clinical research entrepreneurial enterprises were to resurface...posted by: Dean Gesme, MD

Febrile Neutropenia Pts Treated Quicker Under New Protocol (Medscape Medical News)

Frankly, I have never thought of Febrile Neutropenia as a topic for a pathway, but it makes perfect sense. We...posted by: Winston Wong, PharmD

Roche's Perjeta Regimen Approved In Europe For Use Before Surgery In Early Stage Aggressive Breast Cancer (Roche)

This approval comes after US approval for the same indication and is noteworthy as the first drug approved under...posted by: Debu Tripathy, MD

ASCO Value Framework: A Step Forward or Back? (AVBCC/VBCC Perspectives)

I enjoyed Ted Okons' comment on the ASCO value proposition. (Hi Ted, when are we going to have that dinner???...posted by: Thomas Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Ipsen has 1 new job posted.


Dava Oncology has 1 new job posted.


Bayer has 7 jobs posted.


Seattle Genetics has 3 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
PARD +40.00%
TLOG +15.32%
EXEL +8.17%
NYMX -7.03%
GALT -4.68%
CTIX -3.98%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: August 18, 2015
Company: Seattle Genetics, Inc.
Product: Adcetris® (brentuximab vedotin)

Date: August 27, 2015
Company: Bristol-Myers Squibb Co.
Product: Opdivo® (nivolumab)

Date: September 5, 2015
Company: Tesaro
Product: rolapitant

See All OBR Radar items»